Cantor Fitzgerald Reiterates Overweight on Xenon Pharmaceuticals, Maintains $58 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Xenon Pharmaceuticals (NASDAQ:XENE) and maintained a $58 price target.
June 21, 2023 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst reiterates Overweight rating on Xenon Pharmaceuticals (XENE) and maintains $58 price target.
The reiteration of the Overweight rating and maintenance of the $58 price target by Cantor Fitzgerald analyst Charles Duncan indicates a positive outlook for Xenon Pharmaceuticals. This news is likely to have a positive short-term impact on XENE's stock price as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100